|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.18 USD | +0.51% |
|
+0.82% | +1.60% |
| 02-03 | Exact Sciences Corp. Announces A Significant Milestone for Its Oncotype DX Breast Recurrence Score Test | CI |
| 01-30 | The Fed's Next Chair: Reformist, Realist, or Rubber Stamp? |  |
| Capitalization | 19.58B 16.57B 15.19B 14.39B 26.72B 1,774B 27.93B 177B 69.89B 854B 73.43B 71.92B 3,074B | P/E ratio 2025 * |
-164x | P/E ratio 2026 * | 253x |
|---|---|---|---|---|---|
| Enterprise value | 21B 17.77B 16.29B 15.43B 28.65B 1,902B 29.95B 189B 74.94B 916B 78.74B 77.12B 3,296B | EV / Sales 2025 * |
6.5x | EV / Sales 2026 * | 5.62x |
| Free-Float |
98.92% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Exact Sciences Corporation
| 1 day | +0.51% | ||
| 1 week | +0.82% | ||
| Current month | +0.82% | ||
| 1 month | +1.53% | ||
| 3 months | +55.91% | ||
| 6 months | +139.06% | ||
| Current year | +1.60% |
| 1 week | 102.13 |  | 103.42 |
| 1 month | 101.83 | | 103.42 |
| Current year | 101.51 | | 103.42 |
| 1 year | 38.81 | | 103.42 |
| 3 years | 38.81 | | 103.42 |
| 5 years | 29.27 | | 158 |
| 10 years | 4.67 | | 159.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kevin Conroy
CEO | Chief Executive Officer | 60 | 17/03/2009 |
Aaron Bloomer
DFI | Director of Finance/CFO | 40 | 14/04/2024 |
| Chief Tech/Sci/R&D Officer | - | 31/12/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Conroy
CHM | Chairman | 60 | 20/03/2014 |
| Director/Board Member | 71 | 28/04/2009 | |
Daniel Levangie
BRD | Director/Board Member | 76 | 18/07/2010 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -2.74% | 6.8% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.51% | +0.82% | +92.75% | +50.47% | 19.58B | |
| +3.82% | -4.96% | -12.92% | +37.97% | 2.86B | |
| -1.21% | -3.12% | -1.96% | -12.50% | 2.71B | |
| -4.25% | -14.76% | +101.15% | +63.76% | 2.43B | |
| -10.49% | -3.05% | +477.86% | - | 1.34B | |
| +7.20% | -0.78% | -55.54% | -69.22% | 1B | |
| +6.10% | -5.26% | -13.12% | +17.57% | 1B | |
| -3.36% | -9.62% | +11.66% | -9.77% | 815M | |
| +0.09% | -0.82% | -2.75% | -7.01% | 777M | |
| -7.43% | -8.13% | - | - | 541M | |
| Average | -0.90% | -3.29% | +66.35% | +8.91% | 3.31B | |
| Weighted average by Cap. | -0.00% | -1.41% | +79.87% | +36.96% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.23B 2.73B 2.51B 2.37B 4.41B 293B 4.61B 29.12B 11.53B 141B 12.11B 11.86B 507B | 3.67B 3.1B 2.85B 2.7B 5B 332B 5.23B 33.07B 13.09B 160B 13.76B 13.47B 576B |
| Net income | -118M -99.85M -91.51M -86.67M -161M -10.69B -168M -1.06B -421M -5.14B -442M -433M -18.52B | 79.26M 67.09M 61.49M 58.24M 108M 7.18B 113M 715M 283M 3.46B 297M 291M 12.44B |
| Net Debt | 1.42B 1.2B 1.1B 1.04B 1.93B 128B 2.02B 12.77B 5.06B 61.78B 5.31B 5.2B 222B | 1.03B 875M 802M 760M 1.41B 93.66B 1.47B 9.32B 3.69B 45.09B 3.88B 3.8B 162B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/02/26 | 103.18 $ | +0.51% | 4,725,332 |
| 05/02/26 | 102.66 $ | +0.38% | 3,219,250 |
| 04/02/26 | 102.27 $ | -0.23% | 2,711,878 |
| 03/02/26 | 102.51 $ | +0.01% | 1,436,088 |
| 02/02/26 | 102.50 $ | +0.16% | 1,024,664 |
Delayed Quote Nasdaq, February 06, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EXAS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition